Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care

Detalles Bibliográficos
Autores principales: Nazha, Aziz, Sekeres, Mikkael A., Komrokji, Rami, Steensma, David P., Kantarjian, Hagop, Roboz, Gail, Fenaux, Pierre, Prebet, Thomas, Azarnia, Nozar, Zbyszewski, Patrick S., Fruchtman, Steven M., Santini, Valeria, Silverman, Lewis R., Platzbecker, Uwe, Garcia-Manero, Guillermo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802598/
https://www.ncbi.nlm.nih.gov/pubmed/29238044
http://dx.doi.org/10.1038/s41408-017-0018-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802598/
https://www.ncbi.nlm.nih.gov/pubmed/29238044
http://dx.doi.org/10.1038/s41408-017-0018-7

Ejemplares similares